A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN)
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Secukinumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Registrational; Therapeutic Use
- Acronyms GCAptAIN
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 May 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2024 Planned End Date changed from 20 Jul 2027 to 2 Jul 2027.
- 25 Apr 2024 Planned primary completion date changed from 29 Apr 2025 to 11 Apr 2025.